tbuckley/cabot-search huggingface dataset:
Distinct Roles for Secreted Semaphorin Signaling in Spinal Motor Axon Guidance
Authors: Andrea B. Huber, Artur Kania, Tracy S. Tran, Chenghua Gu, Natalia de Marco Garcia, Ivo Lieberam, Dontais Johnson, Thomas M. Jessell, David D. Ginty, Alex L. Kolodkin
Journal: Neuron (2006)
TCTAP C-223 Endovascular Treatment for the Native Popliteal Artery After Bypass Surgery Due to Popliteal Artery Entrapment Syndrome: How Can We Evaluate the Intravascular Imaging at the Distal Anastomosis Site?
Authors: Keisuke Nakabayashi, Hiroshi Ando, Nobuhito Kaneko, Minoru Shimizu
Journal: Journal of the American College of Cardiology (2017)
TCTAP C-004 Right Coronary Artery Ostium Occlusion and a Cardiac Arrest After Six Days of Modified Yacoub Operation for Aortic Valve Ring Dilatation Due to Marfan Syndrome but Was Able to Rescue by Emergent Carefully PCI Observing IVUS
Authors: Hiroshi Okumura, Kotaro Obunai
Journal: Journal of the American College of Cardiology (2017)
T-cell receptor (TCR) DNA deep sequencing to evaluate clonality of tumor-infiltrating lymphocytes (TILs) in early-stage breast cancer patients (pts) receiving preoperative cryoablation (cryo) and/or ipilimumab (ipi).
Authors: David B. Page, Adi Diab, Jianda Yuan, Zhiwan Dong, Ryan Emerson, Harlan Robins, David Redmond, Chunjun Zhao, Zhenyu Mu, Phillip Wong, Stephen Barnett Solomon, Virgilio Sacchini, Monica Morrow, Edi Brogi, Sujata Patil, Jedd D. Wolchok, Clifford A. Hudis, Larry Norton, James Patrick Allison, Heather L. McArthur
Journal: Journal of Clinical Oncology (2014)

3021 Background: In mice, cryo combined with cytotoxic T lymphocyte antigen 4 (CTLA-4) blockade increases antigen-specific TILs, generating a synergistic rejection of secondary tumors. In humans, breast cancer antigens are shared across pts in low frequency and are incompletely characterized. Thus, to evaluate for antigen-specific TILs in pts receiving cryo and/or the anti-CTLA-4 antibody, ipi, we employed deep sequencing of TCR CDR3 region DNA, which provides a quantitative measurement of the frequency of individual T cell clones, each putatively reactive to a unique antigen. Methods: 19 pts were treated with cryo (7 pts), single-dose ipi at 10mg/kg (6 pts), or cryo+ipi (6 pts). Core biopsy (Bx) +/- cryo was performed 7-10 days prior to standard-of-care mastectomy and ipi was given 1-5 days before core Bx. From available specimens, DNA was sequenced using the immunoSEQ™ assay. Utilizing CDR3 sequence copy number, the frequency of each unique T cell clone was determined. Nonparametric analyses were conducted on derivative metrics including T cell %, clonal overlap, and clonality. Results: In core Bx’s, T cell % (median 6.8%, 0.6-30.7%) and clonality (median 0.13, 0.09-0.4) varied across pts, with a higher T cell % in poorly differentiated lesions (p=.03). Cryo reduced T cell counts but induced a polyclonal infiltrate (p=.02) with low clonal overlap, indicating influx of new clones. For the 3 ipi alone pts for whom Bx and mastectomy tissue were available, clonal repertoire appeared closer to baseline, as measured by clonality and overlap. Combination cryo+ipi frequently expanded the proportion of the most dominant (top 5) clones (3/6 cases), an effect which was rarely observed with monotherapy (1/8 cases). Conclusions: Cryo-associated polyclonality and influx of new clones may be related to cryo-mediated cell death, antigen release, and T cell engagement. A cryo+ipi mediated surge of the most dominant clones may reflect synergistic activation of a clonal subset. These findings call for further characterization of therapy-induced dominant clones, and support repertoire analyses in breast cancer. Clinical trial information: NCT01502592.
Bioresorbable Scaffold
Authors: Yohei Sotomi, Yoshinobu Onuma, Carlos Collet, Erhan Tenekecioglu, Renu Virmani, Neal S. Kleiman, Patrick W. Serruys
Journal: Circulation Research (2017)

In the era of drug-eluting stents, large-scale randomized trials and all-comer registries have shown excellent clinical results. However, even the latest-generation drug-eluting stent has not managed to address all the limitations of permanent metallic coronary stents, such as the risks of target lesion revascularization, neoatherosclerosis, preclusion of late lumen enlargement, and the lack of reactive vasomotion. Furthermore, the risk of very late stent, although substantially reduced with newer-generation drug-eluting stent, still remains. These problems were anticipated to be solved with the advent of fully biodegradable devices. Fully bioresorbable coronary scaffolds have been designed to function transiently to prevent acute recoil, but have retained the capability to inhibit neointimal proliferation by eluting immunosuppressive drugs. Nevertheless, long-term follow-up data of the leading bioresorbable scaffold (Absorb) are becoming available and have raised a concern about the relatively higher incidence of scaffold thrombosis. To reduce the rate of clinical events, improvements in the device, as well as implantation procedure, are being evaluated. This review will focus on the current CE-mark approved bioresorbable scaffolds, their basic characteristics, and clinical results. In addition, we summarize the current limitations of bioresorbable scaffold and their possible solutions.
A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models
Authors: Chao Shan, Antonio E Muruato, Bruno T D Nunes, Huanle Luo, Xuping Xie, Daniele B A Medeiros, Maki Wakamiya, Robert B Tesh, Alan D Barrett, Tian Wang, Scott C Weaver, Pedro F C Vasconcelos, Shannan L Rossi, Pei-Yong Shi
Journal: Nature Medicine (2017)
Listeria monocytogenes meningitis in the Netherlands, 1985–2014: A nationwide surveillance study
Authors: Merel M. Koopmans, Merijn W. Bijlsma, Matthijs C. Brouwer, Diederik van de Beek, Arie van der Ende
Journal: Journal of Infection (2017)

ObjectivesListeria monocytogenes can cause sepsis and meningitis. We report national surveillance data on L. monocytogenes meningitis in the Netherlands, describing incidence changes, genetic epidemiology and fatality rate.MethodsWe analyzed data from the Netherlands Reference Laboratory of Bacterial Meningitis for cases of L. monocytogenes meningitis. Strains were assessed by serotyping and bacterial population structure by multi-locus sequence typing.ResultsA total of 375 cases of Listeria meningitis were identified between 1985 and 2014. Peak incidence rates were observed in neonates (0.61 per 100,000 live births) and older adults (peak at 87 year; 0.53 cases per 100,000 population of the same age). Neonatal listerial meningitis decreased 17-fold from 1.95 per 100,000 live births between 1985 and 1989, to 0.11 per 100,000 live births between 2010 and 2014. Overall case fatality rate was 31%, in a multivariate analysis older age and concomitant bacteremia were associated with mortality (both p < 0.01). Clonal complexes (CC) CC1, CC2 and CC3 decreased over time from respectively 32% to 12%, 33% to 9% and 10% to 2% (all p < 0.001), while CC6 increased from 2% to 26% (p < 0.001).ConclusionsThe incidence of neonatal listerial meningitis has declined over the past 25 years. The genotype CC6 has become the predominant genotype in listerial meningitis in the Netherlands. Mortality of listeria meningitis has remained high.
STUDIES IN EXPERIMENTAL EXTRACORPOREAL THROMBOSIS
Authors: Takuji Shionoya
Journal: The Journal of Experimental Medicine (1927)

1. Effects of anticoagulants, heparin and hirudin, on extracorporeal thrombosis were studied in thirty-three experiments by means of the extracorporeal vascular loop. In spite of adequate single doses of the anticoagulants white thrombi are formed and obstruction to flow may follow in the course of time, but the formation of red thrombi is markedly retarded. 2. The new method throws some light on the mechanics of thrombosis. The influences of foreign surfaces, of irregularities on the surface of the vessels, of whirlpools and of eddying motion of the blood current and of slowing and of stagnation with consequent prolonged contact with foreign surfaces are demonstrated, and these are analyzed in respect to the laying down of platelets and leucocytes. 3. The structure of white thrombi formed after anticoagulant injection is almost identical with that described by Welch. In one respect, however, the present results appear to differ from his: the formation of fibrin is postponed and retarded, and hence the collections of platelets are deposited in greater amount.
Multigene Panel Testing and Breast Cancer Risk
Authors: Elias I. Obeid, Michael J. Hall, Mary B. Daly
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
포스터발표 : 그랜드볼룸 ; 식도정맥류 출혈 고위험군 환자의 특징적인 내시경초음파 소견 (초)
Authors: 심재준, 김병호, 조준형, 박재현, 조창현, 황보영, 장재영, 동석호, 김효종, 장영운, 장린
Journal: Clinical and Molecular Hepatology (2010)
Implementation of a written chemotherapy consent form with explicit goals of treatment in a university center.
Authors: Brendan F. Curley, Nilay Shah, Sijin Wen, Mohammed Almubarak, Michael Craig, Michael David Newton
Journal: Journal of Clinical Oncology (2014)

6634 Background: The American Society of Clinical Oncology (ASCO) has stated that consent to treatment with chemotherapy is an important part of the delivery of quality cancer care. Best practices dictate that consent conversations should be well documented in the patient record. Discussion of goals of treatment can be difficult for physicians and patients, however research has shown that patients often mistakenly believe that therapy with palliative intent is in fact curative. The implementation of a written consent form with goals of care in an academic practice has not been studied. Methods: As part of the inaugural ASCO Quality Training Program, a quality improvement project that focuses on the implementation of a written chemotherapy consent with incorporated goals of treatment was designed and implemented. Chemotherapy consent documentation and goals of therapy were retrospectively collected on all patients receiving a new line of chemotherapy. The written chemotherapy consent form was implemented on July 1, 2013; patient data was collected for the duration of 2013, and divided into pre and post intervention data. Patients on clinical trials were excluded from analysis, as written consent is required on protocol. Results: Data was collected from 546 patients, with 224 in the pre-intervention group and 322 in the post-intervention group. Documentation of chemotherapy consent decreased from 63% to 52% (p =0.011) when written consent was required. However, documentation of goals of care improved dramatically with 95% of patients having explicit goals of care documented with written chemotherapy consent, compared to 48% of those that consented orally (p<0.0001). Conclusions: Implementation of written consent that is reviewed and signed by the patient may initially reduce compliance with the consent process when compared to documenting an oral consent in the patient’s chart. However, written consent appears to drastically improve documentation of treatment goals.
Genomic Analysis of Thymic Epithelial Tumors Identifies Novel Subtypes Associated with Distinct Clinical Features
Authors: Hyun-Sung Lee, Hee-Jin Jang, Rohan Shah, David Yoon, Masatsugu Hamaji, Ori Wald, Ju-Seog Lee, David J. Sugarbaker, Bryan M. Burt
Journal: Clinical Cancer Research (2017)

Abstract Purpose: To reconcile the heterogeneity of thymic epithelial tumors (TET) and gain deeper understanding of the molecular determinants of TETs, we set out to establish a clinically relevant molecular classification system for these tumors. Experimental Design: Molecular subgrouping of TETs was performed in 120 patients from The Cancer Genome Atlas using a multidimensional approach incorporating analyses of DNA mutations, mRNA expression, and somatic copy number alterations (SCNA), and validated in two independent cohorts. Results: Four distinct molecular subtypes of TETs were identified. The most commonly identified gene mutation was a missense mutation in General Transcription Factor II-I (GTF2I group), which was present in 38% of patients. The next group was identified by unsupervised mRNA clustering of GTF2I wild-type tumors and represented TETs enriched in expression of genes associated with T-cell signaling (TS group; 33%). The remaining two groups were distinguished by their degree of chromosomal stability (CS group; 8%) or instability (CIN group; 21%) based upon SCNA analyses. Disease-free survival and overall survival were favorable in the GTF2I group and unfavorable in the CIN group. These molecular subgroups were associated with TET histology and clinical features including disease-free survival. Finally, we demonstrate high expression of PD1 mRNA and correlation of PD1 and CD8A in the TS subgroup. Conclusions: Molecular subtyping of TETs is associated with disease-free and overall survival. Classification of TETs by a molecular framework could aid in the refinement of staging and in the discovery and development of rational treatment options for patients with TETs. Clin Cancer Res; 23(16); 4855–64. ©2017 AACR.
Autologous Stem Cell Transplantation for Patients with Early Progression of Follicular Lymphoma- Retrospective Analysis of 2 Randomized Trials of the German Low Grade Lymphoma Study Group (GLSG)
Authors: Vindi Jurinovic, Bernd Metzner, Michael Pfreundschuh, Norbert Schmitz, Hannes Wandt, Christian Peschel, Martin Dreyling, Wolfgang Hiddemann, Eva Hoster, Michael Unterhalt, Oliver Weigert
Journal: Blood (2016)
Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status
Authors: Tsuyoshi Hamada, Yin Cao, Zhi Rong Qian, Yohei Masugi, Jonathan A. Nowak, Juhong Yang, Mingyang Song, Kosuke Mima, Keisuke Kosumi, Li Liu, Yan Shi, Annacarolina da Silva, Mancang Gu, Wanwan Li, NaNa Keum, Xuehong Zhang, Kana Wu, Jeffrey A. Meyerhardt, Edward L. Giovannucci, Marios Giannakis, Scott J. Rodig, Gordon J. Freeman, Daniel Nevo, Molin Wang, Andrew T. Chan, Charles S. Fuchs, Reiko Nishihara, Shuji Ogino
Journal: Journal of Clinical Oncology (2017)

Purpose Blockade of the programmed cell death 1 (PDCD1, PD-1) immune checkpoint pathway can improve clinical outcomes in various malignancies. Evidence suggests that aspirin (a widely used nonsteroidal anti-inflammatory drug) not only prolongs colorectal cancer survival, but can also activate T cell-mediated antitumor immunity and synergize with immunotherapy through inhibition of prostaglandin E2 production. We hypothesized that the survival benefit associated with aspirin might be stronger in colorectal carcinoma with a lower CD274 (PDCD1 ligand 1, PD-L1) expression level that resulted in lower signaling of the immune checkpoint pathway. Patients and Methods Using data from 617 patients with rectal and colon cancer in the Nurses' Health Study and the Health Professionals Follow-Up Study, we examined the association of postdiagnosis aspirin use with patient survival in strata of tumor CD274 expression status measured by immunohistochemistry. We used multivariable Cox proportional hazards regression models to control for potential confounders, including disease stage, microsatellite instability status, CpG island methylator phenotype, long interspersed nucleotide element-1 methylation, cyclooxygenase-2 (PTGS2), and CDX2 expression, and KRAS, BRAF, and PIK3CA mutations. Results The association of postdiagnosis aspirin use with colorectal cancer-specific survival differed by CD274 expression status ( Pinteraction < .001); compared with aspirin nonusers; multivariable-adjusted hazard ratios for regular aspirin users were 0.16 (95% CI, 0.06 to 0.41) in patients with low CD274 and 1.01 (95% CI, 0.61 to 1.67) in patients with high CD274. This differential association seemed consistent in patients with microsatellite-stable or PIK3CA wild-type disease and in strata of PTGS2 expression, CDX2 expression, tumor-infiltrating lymphocytes, or prediagnosis aspirin use status. Conclusion The association of aspirin use with colorectal cancer survival is stronger in patients with CD274-low tumors than CD274-high tumors. Our findings suggest a differential antitumor effect of aspirin according to immune checkpoint status.
Autoreactive T Cells and Chronic Fungal Infection Drive Esophageal Carcinogenesis
Authors: Feng Zhu, Jami Willette-Brown, Na-Young Song, Dakshayani Lomada, Yongmei Song, Liyan Xue, Zane Gray, Zitong Zhao, Sean R. Davis, Zhonghe Sun, Peilin Zhang, Xiaolin Wu, Qimin Zhan, Ellen R. Richie, Yinling Hu
Journal: Cell Host & Microbe (2017)
Membrane permeation of arginine-rich cell-penetrating peptides independent of transmembrane potential as a function of lipid composition and membrane fluidity
Authors: Rike Wallbrecher, Tobias Ackels, R. Alis Olea, Marco J. Klein, Lucie Caillon, Jürgen Schiller, Petra H. Bovée-Geurts, Toin H. van Kuppevelt, Anne S. Ulrich, Marc Spehr, Merel J.W. Adjobo-Hermans, Roland Brock
Journal: Journal of Controlled Release (2017)

Cell-penetrating peptides (CPPs) are prominent delivery vehicles to confer cellular entry of (bio-) macromolecules. Internalization efficiency and uptake mechanism depend, next to the type of CPP and cargo, also on cell type. Direct penetration of the plasma membrane is the preferred route of entry as this circumvents endolysosomal sequestration. However, the molecular parameters underlying this import mechanism are still poorly defined. Here, we make use of the frequently used HeLa and HEK cell lines to address the role of lipid composition and membrane potential. In HeLa cells, at low concentrations, the CPP nona-arginine (R9) enters cells by endocytosis. Direct membrane penetration occurs only at high peptide concentrations through a mechanism involving activation of sphingomyelinase which converts sphingomyelin into ceramide. In HEK cells, by comparison, R9 enters the cytoplasm through direct membrane permeation already at low concentrations. This direct permeation is strongly reduced at room temperature and upon cholesterol depletion, indicating a complex dependence on membrane fluidity and microdomain organisation. Lipidomic analyses show that in comparison to HeLa cells HEK cells have an endogenously low sphingomyelin content. Interestingly, direct permeation in HEK cells and also in HeLa cells treated with exogenous sphingomyelinase is independent of membrane potential. Membrane potential is only required for induction of sphingomyelinase-dependent uptake which is then associated with a strong hyperpolarization of membrane potential as shown by whole-cell patch clamp recordings. Next to providing new insights into the interplay of membrane composition and direct permeation, these results also refute the long-standing paradigm that transmembrane potential is a driving force for CPP uptake.
Immunopharmacodynamic response to blinatumomab in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL).
Authors: Andrea Schub, Virginie Nägele, Gerhard Zugmaier, Christian Brandl, Youssef Hijazi, Max S. Topp, Peter Kufer, Andreas Wolf, Matthias Klinger
Journal: Journal of Clinical Oncology (2013)

7020 Background: Blinatumomab is an anti-CD19/anti-CD3 bispecific T cell engager (BiTE) that induces target cell-dependent, polyclonal T cell activation and proliferation, resulting in redirected lysis of CD19 + target cells. Methods: In a phase 2 study, adult patients (N=36) with relapsed/refractory B-precursor ALL received continuous blinatumomab IV infusion for 28 days in ≤5 treatment/consolidation cycles. Whole blood and serum samples were collected throughout treatment and analyzed for lymphocyte subpopulations, cytokines, granzyme B, and blinatumomab serum concentrations. Results: Lymphocytes in all patients responded in a similar fashion. After infusion start, peripheral B cell counts dropped to ≤1 B cell/μL in &lt;1 week and remained undetectable throughout treatment. Peripheral T cells showed a redistribution characterized by swift disappearance within the first 2-6 hrs and subsequent recovery to baseline within several days. Otherwise, T cell counts remained at least stable in most patients. In some patients even an expansion of the T cell compartments was observed, most likely due to specific proliferation of activated T cells but could not be defined as prerequisite for treatment efficacy. During the first infusion days, a significant proportion of T cells newly expressed the activation marker CD69, and the T cell effector molecule granzyme B was detectable in serum. Additionally, a transient cytokine release dominated by IL-10, IL-6 and IFN-γ was observed in most patients shortly after first infusion start, which was alleviated or absent in subsequent cycles. Blinatumomab serum steady state concentrations (mean±SD) were 198±61 pg/mL and 694±236 pg/mL at doses of 5 and 15 μg/m²/d, respectively, which is comparable to those from previous studies. Conclusions: Immunopharmacodynamic response to blinatumomab was characterized by B cell depletion, T cell activation and redistribution, and release of granzyme B and cytokines, suggesting T cell engagement according to the expected BiTE mode of action. The tested pharmacodynamic markers did not allow for predictive differentiation between patients achieving a hematologic response and those who did not. Clinical trial information: NCT01209286.
Obesity and Cesarean Section—Reply
Authors: Jorge E. Chavarro, Changzheng Yuan, Audrey J. Gaskins
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Inactivation of the INK4A/ARF (CDKN2) locus Cooperates with HMGA1 in T-Cell Leukemogenesis.
Authors: Linda Resar, Francescopaolo Di Cello, Surajit Dhara, Jeanne Kowalski, Ossama Elbahlouh, Joelle Hillion, Stuart Winter, Richard S. Larson, David Huso
Journal: Blood (2009)